Clinical Trials Directory

Trials / Completed

CompletedNCT07190911

Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 COVID-19 (Covid-Smell)

Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 (Covid-Smell)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Centre Hospitalier Universitaire de la Guadeloupe · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.

Detailed description

The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.

Conditions

Interventions

TypeNameDescription
OTHEROlfactory rehabilitation consists of smelling a series of spices every day for 2 monthsOlfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin. This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8 Allergies to certain spices will be noted at the start of the study: * in known allergy: change by another spice which belongs to the same chemical category. * in case of allergies to several scents: patient is not included in the study. * in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category. * in case of allergies to several scents occuring during participation: patient is excluded from the study.

Timeline

Start date
2020-11-18
Primary completion
2022-03-09
Completion
2022-03-09
First posted
2025-09-24
Last updated
2025-10-02

Locations

1 site across 1 country: Guadeloupe

Source: ClinicalTrials.gov record NCT07190911. Inclusion in this directory is not an endorsement.